Sarissa Capital Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $205K | Buy |
+950
| New | +$182K | 0.12% | 10 |
|
|
2024
Q4 | – | Sell |
-26,950
| Closed | -$5.22M | – | 9 |
|
|
2024
Q3 | $5.22M | Sell |
26,950
-616,050
| -96% | -$129M | 1.3% | 7 |
|
|
2024
Q2 | $149M | Hold |
643,000
| – | – | 25.16% | 1 |
|
|
2024
Q1 | $139M | Hold |
643,000
| – | – | 24.26% | 2 |
|
|
2023
Q4 | $166M | Hold |
643,000
| – | – | 25.64% | 2 |
|
|
2023
Q3 | $165M | Hold |
643,000
| – | – | 22.26% | 2 |
|
|
2023
Q2 | $183M | Hold |
643,000
| – | – | 18.23% | 2 |
|
|
2023
Q1 | $179M | Hold |
643,000
| – | – | 22.86% | 2 |
|
|
2022
Q4 | $178M | Hold |
643,000
| – | – | 21.19% | 3 |
|
|
2022
Q3 | $172M | Hold |
643,000
| – | – | 19.4% | 2 |
|
|
2022
Q2 | $131M | Hold |
643,000
| – | – | 13.2% | 3 |
|
|
2022
Q1 | $135M | Hold |
643,000
| – | – | 12.8% | 3 |
|
|
2021
Q4 | $154M | Hold |
643,000
| – | – | 13.35% | 4 |
|
|
2021
Q3 | $182M | Hold |
643,000
| – | – | 14.28% | 4 |
|
|
2021
Q2 | $223M | Hold |
643,000
| – | – | 17.7% | 2 |
|
|
2021
Q1 | $180M | Hold |
643,000
| – | – | 17.24% | 2 |
|
|
2020
Q4 | $157M | Hold |
643,000
| – | – | 16.07% | 3 |
|
|
2020
Q3 | $182M | Hold |
643,000
| – | – | 21.47% | 1 |
|
|
2020
Q2 | $172M | Hold |
643,000
| – | – | 19.14% | 1 |
|
|
2020
Q1 | $203M | Hold |
643,000
| – | – | 25.95% | 1 |
|
|
2019
Q4 | $191M | Hold |
643,000
| – | – | 15.84% | 2 |
|
|
2019
Q3 | $150M | Hold |
643,000
| – | – | 18.76% | 3 |
|
|
2019
Q2 | $150M | Buy |
643,000
+118,342
| +23% | +$27.3M | 18.75% | 3 |
|
|
2019
Q1 | $124M | Buy |
524,658
+62,800
| +14% | +$19.8M | 18.67% | 2 |
|
|
2018
Q4 | $139M | Hold |
461,858
| – | – | 30.8% | 1 |
|
|
2018
Q3 | $163M | Hold |
461,858
| – | – | 36% | 1 |
|
|
2018
Q2 | $134M | Buy |
461,858
+48,000
| +12% | +$13.5M | 26.87% | 1 |
|
|
2018
Q1 | $113M | Hold |
413,858
| – | – | 26.22% | 1 |
|
|
2017
Q4 | $132M | Buy |
413,858
+30,000
| +8% | +$9.62M | 33.75% | 1 |
|
|
2017
Q3 | $120M | Hold |
383,858
| – | – | 37.1% | 1 |
|
|
2017
Q2 | $104M | Buy |
383,858
+73,858
| +24% | +$19.5M | 34.77% | 1 |
|
|
2017
Q1 | $84.8M | Hold |
310,000
| – | – | 33.49% | 2 |
|
|
2016
Q4 | $87.9M | Hold |
310,000
| – | – | 24.21% | 2 |
|
|
2016
Q3 | $97M | Hold |
310,000
| – | – | 22.35% | 2 |
|
|
2016
Q2 | $75M | Hold |
310,000
| – | – | 21.28% | 2 |
|
|
2016
Q1 | $80.7M | Hold |
310,000
| – | – | 17.78% | 3 |
|
|
2015
Q4 | $95M | Buy |
+310,000
| New | +$89.1M | 18.46% | 1 |
|
Other funds holding BIIB
Sarissa Capital Management's BIIB Position: Q2 2026 in Review
Sarissa Capital Management opened a new position in Biogen (BIIB) in Q2 2026: 950 shares worth $205K. The stake represents 0.12% of the portfolio and ranks #10 among its holdings. This is a return to the name: Sarissa Capital Management previously reported a position in BIIB as recently as Q3 2024.
Sarissa Capital Management first reported a position in BIIB in Q4 2015 and has held it in 37 quarters since. The position peaked at $223M in Q2 2021. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Sarissa Capital Management held 950 shares of Biogen worth $205K as of Q2 2026.
- Biogen was a new Sarissa Capital Management position in Q2 2026.
- Biogen made up 0.12% of Sarissa Capital Management's portfolio in Q2 2026, its #10 holding.
- Sarissa Capital Management first reported a position in Biogen in Q4 2015 and has held it in 37 quarters since.
- Sarissa Capital Management's Biogen position peaked at $223M in Q2 2021.
- 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Sarissa Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.